Cholesterol Newswire

Cholesterol Newswire

Comprehensive Real-Time News Feed for Cholesterol.

Results 1 - 20 of 4,092 in Cholesterol

  1. FDA Approves Second Drug in New Class of Cholesterol-Lowering MedicationsRead the original story w/Photo

    Yesterday | MedicineNet

    The U.S. Food and Drug Administration on Thursday approved a second drug that's part of a potent new class of medications that sharply cut levels of "bad" LDL cholesterol . Repatha , an injectable drug, works by blocking a protein that interferes with the liver 's ability to remove LDL cholesterol from the blood.

    Comment?

  2. FDA approves Amgen's cholesterol-lowering drug RepathaRead the original story

    Thursday | WNFL-AM Green Bay

    The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA.

    Comment?

  3. Pricey new cholesterol drug Repatha gets FDA approvalRead the original story w/Photo

    9 hrs ago | Examiner.com

    Amgen Inc. of thousand Oaks, California has been given FDA approval for Repatha injection for some patients who are unable to get their low-density lipoprotein cholesterol under control with current treatment options. It is the 2nd drug in a new class of drugs known as PCSK9 inhibitors, to be granted governmental endorsement for use in addition to diet and maximally-tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia , homozygous familial hypercholesterolemia , or clinical atherosclerotic cardiovascular disease , such as heart attacks or strokes, who require additional lowering of LDL cholesterol.

    Comment?

  4. a Amgen wins FDA approval for cholesterol drug RepathaRead the original story w/Photo

    12 hrs ago | Business Journal

    The move follows FDA's approval last month for a similar drug Praluent, from Sanofi and partner Regeneron Pharmaceuticals Inc. Both Praluent and Repatha belong to a class of injectable cholesterol-lowering drugs known as PCSK9 inhibitors. The FDA on Thursday approved Amgen's Repatha for patients who are unable to control their cholesterol with existing drugs and treatments, specifically, adults with extremely high levels of LDL, or bad cholesterol, due to inherited conditions; and patients with persistently high LDL levels and a history of heart attack, stroke and other cardiovascular problems, according to the Associated Press .

    Comment?

  5. Amgen wins approval for second biotech cholesterol drugRead the original story w/Photo

    13 hrs ago | KBCI CBS 2

    Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades. The drug Repatha could eventually help millions of Americans who face increased risks of heart disease because they cannot control their cholesterol with existing drugs and methods.

    Comment?

  6. FDA approves second drug in new class of cholesterol-lowering medicationsRead the original story w/Photo

    13 hrs ago | WALB-TV Albany

    The U.S. Food and Drug Administration on Thursday approved a second drug that's part of a potent new class of medications that sharply cut levels of "bad" LDL cholesterol. Repatha , an injectable drug, works by blocking a protein that interferes with the liver's ability to remove LDL cholesterol from the blood.

    Comment?

  7. FDA Approves New Cholesterol-Lowering DrugRead the original story w/Photo

    14 hrs ago | Scientific American

    The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA.

    Comment?

  8. Amgen Gets Approval On New Cholesterol DrugRead the original story

    19 hrs ago | SocalTECH.com

    Thousand Oaks-based biopharmaceuticals developer Amgen said Thursday that the U.S. Food and Drug Administration has approved its new, cholesterol lowering drug, Repatha . The medication is being aimed at patients with high LDL-C "bad" cholesterol.

    Comment?

  9. FDA approves another game-changing cholesterol drugRead the original story w/Photo

    17 hrs ago | Washington Examiner

    Federal regulators approved another new cholesterol drug that could help patients with extremely high cholesterol, but will it be too pricey like its predecessor? The Food and Drug Administration approved on late Thursday Repatha, an injection for some patients who are unable to get their cholesterol under control. The drug is the second in a new class of treatments called PCSK9 inhibitors.

    Comment?

  10. US open: Stocks slide as investors remain jittery ahead of Jackson Hole meetingRead the original story w/Photo

    18 hrs ago | Live Charts

    ... Biochem group Amgen climbed 0.58% after the Food and Drug Administration gave the green light to the company's cholesterol treatment. Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and ...

    Comment?

  11. US pre-open: Futures in the red ahead of Jackson Hole symposiumRead the original story w/Photo

    21 hrs ago | Live Charts

    ... Biochem group Amgen climbed 0.48% after the Food and Drug Administration gave the 'green light' to the company's cholesterol treatment. Stock News is provided by Digital Look Corporate Solutions from Sharecast news. Please read the terms and ...

    Comment?

  12. Nicotinic acid inhibits progression of atherosclerosis in mice...Read the original story

    21 hrs ago | CiteULike

    Nicotinic acid is a drug used to reduce the progression of atherosclerosis. Its antiatherosclerotic activity is believed to result from lipid-modifying effects, including its ability to decrease LDL cholesterol and increase HDL cholesterol levels in plasma.

    Comment?

  13. Market Snapshot: U.S. stocks set to fall as volatile week leaves investors waryRead the original story w/Photo

    23 hrs ago | MarketWatch

    ... could make some early gains after the biotech company said the Food and Drug Administration has approved its new cholesterol treatment. which has been heavily influential at times for global equities this week, finished up 5.4%. Analysts voiced ...

    Comment?

  14. New drug could dramatically reduce cholesterolRead the original story

    Yesterday | USA Today

    The Food and Drug Administration on Thursday approved the second in a new class of cholesterol drugs that promises to dramatically lower cholesterol, although at a very high price. Amgen's Repatha, also known New drug could dramatically reduce cholesterol The Food and Drug Administration on Thursday approved the second in a new class of cholesterol drugs that promises to dramatically lower cholesterol, although at a very high price.

    Comment?

  15. FDA Approves Amgen's New Cholesterol Drug RepathaRead the original story

    Thursday | BioSpace

    FDA Approves Amgen's New Cholesterol-Lowering Medication Repathaa - Repatha's Intensive and Predictable LDL-C Lowering Offers a New Treatment Option for Certain Patients With High LDL-C - Repatha Reduced LDL-C by Approximately 54 to 77 Percent Compared With Placebo Repatha Available Next Week in the U.S. THOUSAND OAKS, Calif. Injection.

    Comment?

  16. MomentumWE have OvercomeRead the original story

    Yesterday | American Reporter

    We made food history last week when Indiana declared the Wick's sugar cream as its very own State Pie. I celebrated the event by having my wife tell me I couldn't eat any because of my cholesterol.

    Comment?

  17. FDA Approves Amgen's Cholesterol-Lowering DrugRead the original story w/Photo

    Yesterday | Fox News

    The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease. Last month the FDA approved a similar drug from Regeneron Pharmaceuticals Inc and Sanofi SA.

    Comment?

  18. FDA approves Amgen cholesterol-lowering drug Repatha for some patientsRead the original story w/Photo

    Yesterday | Los Angeles Times

    Amgen has big hopes for cholesterol drug Repatha, which one analyst estimated could reach $4 billion per year in annual sales. Amgen has big hopes for cholesterol drug Repatha, which one analyst estimated could reach $4 billion per year in annual sales.

    Comment?

  19. FDA OKs Cholesterol DrugRead the original story w/Photo

    Yesterday | Investor's Business Daily

    ) drug Repatha, designed for patients with hereditary forms of high cholesterol and who are at high risk of heart disease, won an FDA OK. The approval's scope was similar to Regeneron Pharmaceuticals' (NASDAQ: ) drug Praluent. Concerns remain about ...

    Comment?

  20. Amgen Cholesterol Drug Wins U.S. Approval to Treat Some PatientsRead the original story

    Yesterday | The Washington Post

    Amgen Inc. won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market.

    Comment?